Clinical Trials Logo

Clinical Trial Summary

This study is a controlled, un-blinded, two-arm, randomized (1:1) clinical trial to determine if providing high-risk subjects with a calculated risk score changes the likelihood of pre-exposure prophylaxis (PrEP) uptake.


Clinical Trial Description

All men who have sex with men (MSM) and male-to-female transgender individuals who have sex with men who present to TNC for HIV testing and are at risk for HIV will be offered enrollment in this study (see study schema). Upon enrollment, subjects will be given an Ipad-based computerized questionnaire that assesses their risk perception, demographics, risk behavior, and perception of whether they are a candidate for PrEP. Upon completion of the survey they will be randomized into 1 of 2 arms. Subjects in the intervention arm will receive the results of their risk score based on a risk calculator developed at UCSD and the Center for Disease Control and Prevention's tool for Assessing Risk for Contracting HIV (ARCH, formerly known as the HIV Incidence Risk Index for MSM, or HIRI-MSM), whereas subjects in the control arm will not receive this information. Both groups will receive standard risk reduction counseling. Subjects will be contacted by phone 2 months after enrollment to determine whether they initiated PrEP or not, to re-assess their risk perception, and to provide a link to a final online survey. If subjects have not completed the survey 4 weeks after being provided with the link, they will receive a text-message reminder.

The analysis of the data will begin 12 weeks after the last study subject is enrolled. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02125773
Study type Interventional
Source University of California, San Diego
Contact
Status Completed
Phase N/A
Start date February 19, 2014
Completion date November 8, 2019

See also
  Status Clinical Trial Phase
Completed NCT00065741 - Botanical/Drug Interactions in HIV: Glucuronidation Phase 1
Completed NCT00056953 - Peer Mentors for Adolescents in HIV Affected Families Phase 2
Completed NCT00047931 - HIV-1 Vaccine Test in Uninfected Adult Volunteers Phase 1
Completed NCT03995862 - Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region
Completed NCT00006327 - Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand Phase 3
Completed NCT03086200 - Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals N/A
Completed NCT00076817 - Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm Phase 1
Completed NCT03191474 - Linkage of Transgender Individuals to PrEP N/A
Completed NCT00121121 - Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers Phase 1
Completed NCT00009685 - HIV-1 Vaccine Test in Uninfected Adult Volunteers Phase 1
Completed NCT00031304 - Screening Protocol for HIV Vaccine Studies
Completed NCT00055237 - Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients Phase 2
Terminated NCT00789789 - Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials N/A
Completed NCT01761643 - CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM Phase 4
Completed NCT01418235 - Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults Phase 1
Completed NCT00028119 - HIV Incidence and Participation Retention in Pune, India
Completed NCT00076232 - A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes Phase 3
Completed NCT00004579 - A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection Phase 1
Active, not recruiting NCT00013572 - HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults Phase 1
Completed NCT00001109 - A Blood Test to Look at Cells of the Immune System in Healthy Children N/A